The Histamine Intolerance Test Most People Never Get

A negative allergy panel, a food diary full of reactions and a low DAO level on a lab report add up, for many people, to a diagnosis of histamine intolerance. Almost none of those diagnoses were ever tested blind. When a research team finally ran that test, most of them did not survive it.

I’m Dr. Gurpreet Singh Padda, MD, MBA, MHP, coauthor with Ami Michelle Grimes of The Angry Gut. The video She’s Not Allergic to Her Food. She’s Fermenting It. follows one patient through this. Here the focus is measurement: what a histamine intolerance test can show, which numbers mislead, and where the histamine actually comes from.

What a blinded histamine intolerance test found

Patients referred with suspected histamine intolerance were challenged with histamine and with placebo, without knowing which they received. The diagnosis was ruled out for 84.7% of them, and sixty-two point seven percent had symptoms after the placebo. Just 4 of 59 reacted objectively to histamine and not to placebo, and even those were rated merely plausible.

The blood enzyme test fared no better. DAO levels tended to run lower in people who reacted, at P = .08, but varied so widely in everyone else that the test could not sort patients. Before the challenge, three-quarters had reported improvement on a low-histamine diet, and none reported full resolution.

None of that means the symptoms are imaginary. It means dietary histamine is the wrong target for most people put on the diet, and a partial answer bought with years of subtraction is still a partial answer.

Tryptase and the two rulebooks for mast cell activation

When histamine intolerance falls apart, mast cell activation is often the next label, and there are two competing definitions. The restrictive consensus sets normal serum tryptase at 0 to 11.4 ng/mL and counts an episode when tryptase rises to baseline times 1.2, plus 2 ng/mL, with all three diagnostic criteria met. Its own worked example: from a baseline of 10 ng/mL the bar sits at 14, so a rise to 20 is suggestive. The authors concede the formula favors specificity while sensitivity varies. It is built to avoid false positives, which means it will miss people.

The permissive framework puts prevalence as high as 17% of the general population and admits in its own text that overdiagnosis could be a problem. The restrictive committee answered that the alternative criteria often lack specificity and validation. A computational study of how each rulebook’s wording clusters symptoms found the two mast cell criteria sets agreed at a cosine similarity of 0.55, against 0.86 for two accepted lupus criteria sets. That measures wording, not patients, but wording is exactly what is in dispute.

The practical lesson is simple. A tryptase drawn during an episode and paired with a baseline is the test that matters, and it is the one most often missing from the chart.

Hereditary alpha-tryptasemia explains a number, not an event

A genetic trait raises baseline tryptase in some people. Hereditary alpha-tryptasemia turned up in 4% of healthy donors and 29% of non-clonal mast cell activation cases, and carriers ran higher baseline tryptase. The restrictive criteria suggest considering genotyping at a tryptase of 8 ng/mL or higher.

The genotype predicts less than it seems to. Carriers reported anaphylaxis more often, 76% against 65%. But among 308 patients whose illness did not begin with anaphylaxis, later anaphylaxis appeared in 35% of carriers and 36% of everyone else. Extra gene copies did not push tryptase higher either, 44.1 against 35.2 ng/mL. A genotype can explain a lab value without forecasting what happens next.

The DAO supplement trial, read to the end

When the diet stalls, a DAO enzyme capsule is usually next. One randomized, double-blind trial stands behind it: 100 people with episodic migraine and measured enzyme deficiency, below 80 HDU/ml, treated for one month. Attack duration fell from 6.14 to 4.76 hours on the enzyme and from 7.53 to 6.68 hours on placebo. Only the enzyme arm’s change reached significance on its own, but the two arms did not differ from each other, and attack counts and pain scores fell similarly on both.

That trial studied headaches, not bowels, for a month. Even the restrictive committee lists the enzyme as an unvalidated marker and says it is unclear whether mast cells produce it at all. Nothing bad happened on the capsule, and nothing measurably better happened than on placebo. A supplement market that sells the enzyme on the within-arm result is selling half a sentence.

Where gut histamine is actually made

The better-supported source is the terrain. In mice colonized with stool from IBS patients who had high urinary histamine, gut bacteria produced enough histamine to cause visceral hypersensitivity and mast cell buildup, and blocking the histamine H4 receptor or feeding a low-fermentable diet reversed it. The responsible bacterial strain was abundant in three independent patient cohorts. In people with IBS, cutting fermentable carbohydrate brought pain and urinary histamine down together.

Two biological drivers feed that loop: bacteria fermenting food into histamine, and a leaky wall that lets bacterial fragments prime the lining’s immune cells, a story that begins in Chapter 4 and gets repaired in Chapter 29. This is metaflammation at the gut lining, and a shorter grocery list does not reach it. Look at when your reactions began. An antibiotic course, a gut infection or a surgery in that timeline points upstream.

Repairing the source instead of shrinking the plate

Low-dose naltrexone is often raised in this setting, and its mechanism is routinely described wrong. It is not a mast cell stabilizer and does not act on the mast cell membrane. Opioids can trigger mast cells through a receptor called MRGPRX2, and naltrexone is inactive there.

What it does is indirect. A short blockade of opioid receptors is followed by a rebound in the body’s own endorphin. In fourteen healthy people given a standard dose, the spinal fluid rise was 138% in overweight and obese subjects against 52.1% in lean ones, so the metabolically loaded patient may get the larger rebound, and cortisol rose 28% as well. That endorphin is thought to act on lymphocytes, including regulatory T cells, the least settled link and one resting mostly on mouse work. Separately, naltrexone blunts Toll-like receptor 4 signaling from bacterial fragments in cell and animal studies, which lowers the inflammatory output that keeps gut mast cells primed. No human study has confirmed that step yet.

That makes it a terrain tool, not a membrane tool. The measurements worth tracking are the ones above: paired tryptase, symptom response to a physician-guided reintroduction, and the fermentation picture. Chapter 30 covers the maintenance underneath all of it, and Chapter 32 turns to a bowel that will not move. For every study here with its full numbers and limits, open the Chapter 31 Deep Dive, which also lists questions to bring to your physician.

Frequently asked questions

Is there an accurate test for histamine intolerance?

Not a simple one. Blood DAO levels could not separate reactors from non-reactors in a placebo-controlled challenge study, and most referred patients had the diagnosis excluded once histamine and placebo were compared blind. A supervised, blinded challenge is the most informative approach, and it is rarely done outside research settings. See which biomarkers actually reflect inflammation and repair.

Does a low histamine diet work?

Partly, for some people. In a blinded challenge study, three-quarters of referred patients had reported improvement on the diet beforehand, but none reported resolution, and a majority reacted to placebo during testing. That pattern points away from dietary histamine and toward histamine made by gut bacteria and mast cells primed by a damaged lining. Learn why following every protocol can still leave symptoms unresolved.

What tryptase level suggests mast cell activation?

Under the restrictive consensus, normal serum tryptase runs 0 to 11.4 ng/mL, and an episode counts when tryptase rises above baseline times 1.2 plus 2 ng/mL, alongside the other criteria. From a baseline of 10, that bar is 14. A tryptase of 8 ng/mL or higher is where genotyping for hereditary alpha-tryptasemia is suggested. Read how inflammatory biomarkers are interpreted in practice.

Do DAO supplements help with histamine intolerance?

The only randomized trial studied migraine, not gut symptoms, for one month in people with measured DAO deficiency. Attack duration shortened on the enzyme, but it also shortened on placebo, and the two groups did not differ. The supplement appeared safe. Whether it helps gut reactions has not been tested in a randomized trial. See why capsules work only as named tools for named jobs.

Is hereditary alpha-tryptasemia dangerous?

It raises baseline tryptase, but it forecasts less than people fear. In a cohort of mast cell patients, carriers reported anaphylaxis more often overall. Among patients whose illness did not start with anaphylaxis, though, later anaphylaxis occurred at almost the same rate in carriers and non-carriers, 35% against 36%. Discuss your own history with your physician. Explore how Regen.MD evaluates inflammatory conditions.

Sources

1. Bent, R. K., Kugler, C., Faihs, V., Darsow, U., Biedermann, T., & Brockow, K. (2023). Placebo-controlled histamine challenge disproves suspicion of histamine intolerance. The Journal of Allergy and Clinical Immunology: In Practice, 11(12), 3724-3731.e11. https://doi.org/10.1016/j.jaip.2023.08.030
2. Valent, P., Akin, C., Nedoszytko, B., Bonadonna, P., Hartmann, K., Niedoszytko, M., Brockow, K., Siebenhaar, F., Triggiani, M., Arock, M., Romantowski, J., Górska, A., Schwartz, L. B., & Metcalfe, D. D. (2020). Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. International Journal of Molecular Sciences, 21(23), 9030. https://doi.org/10.3390/ijms21239030
3. Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., Dubravec, M. S., Guggenheim, A. G., Hindman, K. J., Hoffman, B., Kaufman, D. L., Kratzer, S. J., Lee, T. M., Marantz, M. S., Maxwell, A. J., … Molderings, G. J. (2020). Diagnosis of mast cell activation syndrome: a global “consensus-2”. Diagnosis (Berlin, Germany), 8(2), 137-152. https://doi.org/10.1515/dx-2020-0005
4. Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., Sperr, W. R., Alvarez-Twose, I., Horny, H.-P., Sotlar, K., Schwaab, J., Jawhar, M., Zanotti, R., Nilsson, G., Lyons, J. J., … Valent, P. (2021). Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review. The Journal of Allergy and Clinical Immunology: In Practice, 9(11), 3918-3928. https://doi.org/10.1016/j.jaip.2021.06.011
5. González-de-Olano, D., Navarro-Navarro, P., Muñoz-González, J. I., Sánchez-Muñoz, L., Henriques, A., de-Andrés-Martín, A., Peralta-Arjonilla, D., Mayado, A., Jara-Acevedo, M., García-Montero, A. C., Orfao, A., & Álvarez-Twose, I. (2023). Clinical impact of the TPSAB1 genotype in mast cell diseases: a REMA study in a cohort of 959 individuals. Allergy, 79(3), 711-723. https://doi.org/10.1111/all.15911
6. Izquierdo-Casas, J., Comas-Basté, O., Latorre-Moratalla, M. L., Lorente-Gascón, M., Duelo, A., Soler-Singla, L., & Vidal-Carou, M. C. (2018). Diamine oxidase (DAO) supplement reduces headache in episodic migraine patients with DAO deficiency: a randomized double-blind trial. Clinical Nutrition, 38(1), 152-158. https://doi.org/10.1016/j.clnu.2018.01.013
7. Solomon, B. D., & Khatri, P. (2024). Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria. The Journal of Allergy and Clinical Immunology, 155(1), 213-218.e4. https://doi.org/10.1016/j.jaci.2024.09.006
8. De Palma, G., Shimbori, C., Reed, D. E., Yu, Y., Rabbia, V., Lu, J., Jimenez-Vargas, N., Sessenwein, J., Lopez-Lopez, C., Pigrau, M., Jaramillo-Polanco, J., Zhang, Y., Baerg, L., Manzar, A., Pujo, J., Bai, X., Pinto-Sanchez, M. I., Caminero, A., Madsen, K., … Bercik, P. (2022). Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. Science Translational Medicine, 14(655), eabj1895. https://doi.org/10.1126/scitranslmed.abj1895
9. Gordon, R. J., Panigrahi, S. K., Meece, K., Atalayer, D., Smiley, R., & Wardlaw, S. L. (2017). Effects of opioid antagonism on cerebrospinal fluid melanocortin peptides and cortisol levels in humans. Journal of the Endocrine Society, 1(10), 1235-1246. https://doi.org/10.1210/js.2017-00289
10. Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). The European Journal of Neuroscience, 28(1), 20-29. https://doi.org/10.1111/j.1460-9568.2008.06321.x

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 31 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.